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Abstract
Background: microRNAs are single-stranded non-coding RNA sequences of 18 - 24 nucleotides in length. They play
an important role in post-transcriptional regulation of gene expression. Evidences of microRNA acting as
promoter/suppressor of several diseases including cancer are being unveiled. Recent studies have shown that
microRNAs are differentially expressed in disease states when compared with that of normal states. Profiling of
microRNA is a good measure to estimate the differences in expression levels, which can be further utilized to
understand the progression of any associated disease.
Methods: Machine learning techniques, when applied to microRNA expression values obtained from NGS data, could
be utilized for the development of effective disease prediction system. This paper discusses an approach for microRNA
expression profiling, its normalization and a Support Vector based machine learning technique to develop a Cancer
Prediction System. Presently, the system has been trained with data samples of hepatocellular carcinoma, carcinomas
of the bladder and lung cancer. microRNAs related to specific types of cancer were used to build the classifier.
Results: When the system is trained and tested with 10 fold cross validation, the prediction accuracy obtained is
97.56% for lung cancer, 97.82% for hepatocellular carcinoma and 95.0% for carcinomas of the bladder. The system is
further validated with separate test sets, which show accuracies higher than 90%. A ranking based on differential
expression marks the relative significance of each microRNA in the prediction process.
Conclusions: Results from experiments proved that microRNA expression profiling is an effective mechanism for
disease identification, provided sufficiently large database is available.
Keywords: MicroRNA, Expression profiling, Sequence mapping, SVM classifiers
Background
microRNAs belong to the family of non-coding RNAs,
having length around 22 nucleotides and are found in
many eukaryotes including human beings [1]. Recent
studies have identified evidences of its role in wide
variety of biological processes such as normal cell devel-
opment, differentiation, growth control and progres-
sion/suppression of many diseases including cancer [2].
Mature microRNAs may make Watson-Crick base pair-
ing to the 3’ untranslated region of mRNA, causing gene
expression regulation [3–5]. In fact, the gene regulation
is by mRNA degradation or by repression of mRNA
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translation process [6–8]. Studies have undeniably proved
the difference in expression levels of microRNAs in nor-
mal and diseased conditions [9, 10]. Thus, the role of
microRNAs in gene regulation is in turn associated with
the metamorphosis of diseases. Study of microRNAs and
its connection with various diseases lead to developments
in targeted therapy against specific molecular activity [11].
Recent studies have revealed that several microRNAs are
acting similar to oncogenes / tumour suppressors. Initially
identified tumour suppressor microRNAs include miR
143, miR-145, miR-15a, miR-16-1 and let-7 family mem-
bers, whereas oncogenes include miR-21, miR-221 and
miR-155 [12]. Over expression of hsa-Mir-101 inhibits
spreading of lung cancer by reduction in the gene activity
of zeste homolog2 (EZH2) [13], whereas reduced expres-
sion of hsa-let-7c is associated with shorter survival of
lung cancer patients [14]. Expression of β − catenin can
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be regulated by microRNA-33a which results in lung can-
cer cell proliferation [15]. Downregulation of lung cancer
by hsa-mir-30c due to its targeted activity against Rab
18 gene was proved by a qRT-PCR profiling experiment
[16]. Landi et al. reported a scheme with signature of five
microRNAs (miR-25, miR-34c-5p, miR-191, let-7e and
miR-34a) to differentiate both the sub types of lung can-
cer, Adenocarcinoma (AD) and Squamous cell carcinoma
(SCC) [17]. Aberrant expression of several microRNAs
were correlated with bio-pathological and clinical features
of hepatocellular carcinoma (HCC). Over expression of
microRNAs were linked to cancer-associated pathways,
indicating a direct role in liver tumorigenesis. For exam-
ple, upregulation of miR-221 and miR-21 promotes cell
cycle progression, reduces cell death and favours angio-
genesis and invasion. These findings suggest that microR-
NAs can be novel molecular targets for HCC treatment
[18]. Presently, efforts have been made by researchers to
collect and publish association between microRNAs and
various diseases by text mining the available literature.
MiRCancer is one such database extracted from litera-
ture, shows 878 associations between 79 human cancers
and 236 microRNAs [19]. PhenomiR is yet another man-
ually curated database, where deregulation of microRNAs
in diseases is investigated from 542 studies [20].
microRNA profiling application ranges from identi-
fication of microRNAs involved in cell differentiation,
novel microRNA discovery, microRNA : mRNA and
microRNA : protein interactions and as biomarkers. It
is a difficult task due to very low presence (0.01%)
of microRNA in total RNA mass, lack of common
start or stop sequence and very short sequence length.
Despite these challenges, three different strategies were
established - a hybridization based method (microarray,
nCounter), Quantitative reverse transcription PCR (qRT-
PCR) and Next Generation Sequencing (RNA-Seq) [21].
qRT-PCR is suitable for absolute quantification, but less
capable to identify novel microRNAs. Microarray is a
high throughput operation with low cost, but absolute
quantification is difficult. RNA-Seq ensures high accuracy
in distinguishing microRNA with similar sequences and
thereby novel microRNAs can also be detected. Shirley
et al. compared different profiling systems and concluded
that NGS platforms have highest detection sensitivity,
highest differential expression analysis accuracy and high
level of technical re-productivity [22]. Data analysis of
Next Generation Sequencing (NGS) consists of several
steps. A generalized NGS pipeline begins with a prepro-
cessing, where adapter contamination is removed and low
quality reads are trimmed. Next step is mapping of reads
to a reference sequence. Depending upon application, the
reference sequence can be either a genome or a transcript.
NGS reads may contain adapter or fragments of adapter
sequence, which were added during library preparation
step of sequence generation. Adapters are not part of
biological sequence and if not trimmed would be a rea-
son for wrong downstream analysis. Given a read and
an adapter sequence the problem of adapter removal
can be modelled as an optimal semi global sequence
alignment problem. Several of preprocessing tools have
been developed recently for efficient adapter removal
and quality trimming. They differ in accuracy, speed,
memory requirement, capability to trim at 5’ end or 3’
end or both the ends and capable of handling single or
paired end reads. Quite a few algorithms are based on
Watermann Smith sequence alignment algorithm, having
a time complexity of O(mn). Btrim [23] is a very fast tool
that works with a time complexity of O(mn/w), where w
is word length of the computer. FastX, TagCleaner [24]
and SeqTrim [25] are useful only for single end reads.
Besides handling of both single and paired end reads, low
quality trimming can be performed with Trimomatic [26],
AllenTrimmer [27], Cutadapt [28], AdapterRemoval [29]
and Skewer [30].
In genome scale mapping, the reference sequence con-
sists of millions of nucleotides, there could be many
locations where a read has an approximate/exact match.
Around 60 sequence mapping tools were developed after
Next Generation Sequencing came into existence. Accu-
racy, speed, read length support and memory require-
ment are critical parameters in measuring performance
of sequence mapping tools. Speed of operation can be
enhanced by applying limits to the number of mismatches
permitted and the gap lengths allowed. Another possible
way to increase speed is by ignoring read quality score
and single nucleotide polymorphism(SNP) information.
The number of mapped reads decreases with increase in
read length for a given threshold of mismatches permit-
ted. Paired ends map to a reference sequence if the reads
are within a threshold value of insert size. Throughput of
tools that consider paired ends are lesser than those of
single end reads [31].
Generally, sequence mapping starts with the creation
of an index of the reference sequence. Most popular
indexing techniques used in the tools are hash table and
Burrows Wheeler Transform (BWT). Hash table based
indexing keeps a pair - keyword and value, where key-
word is a k-mer generated from the reference sequence
and value returned is the coordinate of matched loca-
tion in the reference sequence. A new index with small
memory requirement, based on BWT, namely FM Index
is the backbone of another set of tools. When compared
with Hash tables, index built time is higher for BWT, but
it works efficiently in cases when a single read matches
with multiple locations. Examples of tools based on BWT
indexing are BWA [32], Bowtie [33] and SOAP2 [34],
whereas SOAP [35], NovoAlign [36], and mrsFast [37]
are tools based on Hash table. Majority of the algorithms
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consider first few tens of base pairs of a read as seed
region. It is relevant due to the fact that chances of errors
in base pairing is feeble in this region. The number of
mismatches allowed in seed region, length of seed region,
number of mismatches allowed in non seed region are the
main input parameters in mapping tools.
The objective of the present study is to develop a can-
cer prediction system using microRNA profiling. This
is accomplished by the application of machine learn-
ing technique on differential expression of specific set
of microRNAs in normal and in tumour samples. Pro-
filing of microRNAs is performed by removing the
adapter sequences, sequence mapping to quantify mature




microRNA transcriptome data for lung cancer, hepa-
tocellular carcinoma and bladder cancer were used to
build a cancer prediction system. Data in Sequence Read
Archives (SRA)format was downloaded from National
Center for Biotechnology Information (NCBI). The lung
cancer data set consists of 41 samples (SRP009408-
microRNA expression profiles in lung cancer tissues ver-
sus adjacent lung tissues using next-gen sequencing). 20
samples of bladder cancer (SRP007946) and 46 samples
of both normal and tumour for hepatocellular carcinoma
(SRP049590) were downloaded. Illumina Genome Ana-
lyzer II was the sequencing machine in all these three
cases. Another 9 samples of lung cancer were down-
loaded to conduct an independent test (SRP040720). The
microRNAs that are linked with up/downregulation of
lung cancer, hepatocellular carcinoma and carcinomas
of the bladder were obtained from microRNA - disease
association databases such as miRCancer [19], PhenomiR
[20] and from review articles on specific types of can-
cer [38]. Mature microRNA sequences were downloaded
from miRBase [39].
MicroRNA profiling
Quantification of mature microRNAs is preferred to pre-
microRNAs since the former show active role in gene
regulation. Several approaches have been employed by
researchers/scientists to quantify microRNAs in NGS
reads. In one of the profiling experiments, mature
microRNA sequence aligned to a read with a maximum
of one mismatch was considered as a hit [40]. Two or
three mismatches for longer reads were allowed in other
experiments [41]. There are examples of studies with a
restriction that exact match between a read and a mature
microRNA were made mandatory to prevent the reads
mapped to paralogs of a given microRNA and to avoid
multiple ambiguous hits [42].
The proposed architecture for cancer prediction system
fromNGS data is depicted in Fig. 1. The sequence of oper-
ations involved in the process is; 1) reads are preprocessed
so that they become devoid of adapter contamination and
satisfy minimum quality threshold and length. 2) Resul-
tant reads are aligned to MirBase V 20. 3) Quantification
of disease specific microRNAs from the samples is deter-
mined. 4) Normalize the read counts 5) Apply machine
learning technique to build a classifier.
To perform preprocessing we used TrimGalore, which
in effect uses two popular tools cutadapt and FastQC.
Adapter removal was done by cutadapt and quality trim-
ming was done by FastQC. In this experiment, we insist
the length of resultant reads to be atleast 20 and the qual-
ity threshold to be at least 30. To align reads to MirBase,
a memory efficient and ultra fast sequence mapping tool,
Bowtie is used [33]. Memory efficiency and speed are
attained by creating an index of the reference sequence.
Bowtie equipped with a tool, bowtie − build, to create the
index. Bowtie alignment policy can be set either by seed
length (-l) and number of mismatches in seed region (-n)
or total number of mismatches (-v) in the entire align-
ment. When a sequence mapping tool like Bowtie is used
to map reads to a mature microRNA sequence, the total
number of aligned reads can be taken as the measure of its
expression level. We used idxstats of samtools [43] to get
the statistics of mapped and unmapped reads against each
microRNA.
Expression normalization
In microRNA profiling, normalization is a critical step
as it tries to correct bias in the data. Several normal-
ization methods are available, specifically applicable to
microarray analysis, Real time PCR and Next Genera-
tion Sequencing. In Next Generation Sequencing, relative
count of microRNA is found by normalizing reads against
total number of reads in the sample or total number of
maps to microRNAs in the sample. The resultant value
is expressed as reads per million to respective library.
Z-score normalization determines the variation of expres-
sion value from the mean in units of standard devia-
tion. In this experiment, the normalized expression of a
microRNA is Z-score value of microRNA expression with
respect to the total mapped microRNAs in the sample.
Differential expression of microRNAs
Normalized expression values of a microRNA from all
samples can be viewed as a vector of n dimensions, where
n is the number of samples. Differential expression in nor-
mal and tumour sample was obtained by finding Euclidean
distance as a measure of degree of difference in expression
values between the samples. If P = (x1, x2, . . . . . . , xn)
and Q = (y1, y2, . . . . . . , yn) are two vectors, the distance
between P and Q is obtained by d =
√
ni=1 (xi − yi)2.
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Fig. 1 General architecture of cancer prediction system
Prediction model by SVM
A prediction model based on Support Vector
Machine(SVM) is used to classify the data samples. SVM
is a supervised machine learning algorithm. It works
by projecting data in input space to a feature space
of higher dimensions. SVM has been selected for this
experiment due to its ability to handle high dimensional
data and due to its higher prediction accuracy. A linear
classifier is based on a discriminant function of the form
f (x) = ωTx + b, where ω is weight vector and b is bias.
ωTx is dot product between two vectors and it is defined
as ωTx = iωixi. A hyperplane is the set of all points with
ωTx = 0, which separates input data into two classes.
The bias, b translate the hyperplane away from the origin.
The closest points to the hyperplane among positive and
negative samples define a margin. Instances in the train-
ing set can be viewed as pair (xi, yi) ∀i = 1, m, where m
is number of instances in the training set. SVMminimizes
the risk of misclassification by maximizing the margin
between the data points. Therefore, SVM is basically an
optimization problem to find out a Lagrangian multiplier,











αiyi = 0, αi ≥ 0, i = 1, . . . ,m
A linear SVM is of no use, if input data instances are
not separable by a linear boundary. Solution to this prob-
lem is mapping of data in to a higher dimensional space
which may exhibit a linear pattern. A non-linear SVM
classifier is based on discriminant function of form f (x) =
ωTφ(x) + b, where φ is a non-linear function. Direct
computation of the function φ is not scalable with the
number of input features. An efficient way of computa-
tion known as kernel trick k is employed to limit the size
of resultant feature space and thus memory and com-
putational requirements. A Pearson VII kernel(PUK) is
defined as


















where ω and σ control half width and trailing factor of
peak, respectively.
We trained and tested classifiers for lung can-
cer, carcinomas of the bladder and hepatocellular
carcinoma separately. We evaluated the performance
of the models with three different kernel functions,
namely Normalized polynomial kernel, RBF Kernel and
Pearson VII kernel(PUK). Normalized polynomial ker-
nel and Pearson VII kernel(PUK) functions were giv-
ing almost same performance. The performance of
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the classifier model was evaluated with the following
measures:
precision = TPTP + FP
True Positive Rate/Recall/Sensitivity = TPTP + FN
False Positive Rate = FPTN + FP
Accuracy = TP + TNTP + TN + FP + FN
Results
microRNA data with respect to sequencing experiments
in lung cancer, hepatocellular carcinoma and carcinomas
of the bladder were retrieved from NCBI. The lung can-
cer data set contains 21 positive and 20 negative samples,
whereas the data sets of hepatocellular carcinoma con-
tains 23 positive and 23 negative samples, and the data
sets of carcinomas of the bladder contains 10 positive and
10 negative samples. Accession codes and total number of
reads in each sample are given in Additional file 1. microR-
NAs associated to each type of cancer were obtained from
the disease association databases such as miRCancer and
Phinomir as well as collected manually from the litera-
ture. List of microRNAs used in our study is given in
Additional file 2. NGS data were pre-processed to remove
adapter sequences as well as to satisfy strict read length
and base pair quality threshold. The pre-processed sam-
ples with number of quality reads are given in Additional
file 3. Cancer-specific microRNAs were mapped against
quality reads using Bowtie. Expression values obtained
were normalized using Z-Score normalization. Additional
file 4 contains normalized expression values of the respec-
tive microRNAs associated with lung cancer. Similarly,
Additional files 5 and 6 show the same information associ-
ated with hepatocellular carcinoma and carcinomas of the
bladder.
Differential expression of a microRNA was computed
as the Euclidean distance between expression values in
normal and tumour samples. microRNAs were ranked by
arranging them in descending order of differential expres-
sion. Table 1 shows the list of top ranked 20 microRNAs
in each type of cancer. These results correlate with proved
role of microRNAs in different experiments. For instance,
over expression of miR 122 downregulates hepatocellu-
lar carcinoma by controlling the expression of Wnt 1,
β-catenin and TCF-4 [44], which is ranked 1st in our
experiment. The second rankedmicroRNA is hsa-miR-21.
Clinical evidence shows that miR-21 acts as tumour sup-
pressor by targeting MAP2K3 gene [45]. microRNA pro-
files for lung cancer diagnosis and prognosis have been
studied by Yanaihara et al. [46] and listed 43 differentially
expressed microRNAs. hsa-miR-21 is one among them,
Table 1 microRNAs associated with lung cancer, hepatocellular
carcinoma and carcinomas of the bladder
Rank Lung cancer Hepatocellular carcinoma Carcinomas of the
bladder
1 hsa-miR-21-5p hsa-miR-122-5p hsa-miR-143-3p
2 hsa-miR-148a-3p hsa-miR-21-5p hsa-miR-200c-3p
3 hsa-let-7g-5p hsa-miR-143-3p hsa-miR-182-5p
4 hsa-miR-101-3p hsa-miR-148a-3p hsa-miR-146b-5p
5 hsa-miR-103a-3p hsa-miR-101-3p hsa-miR-103a-3p
6 hsa-miR-29a-3p hsa-miR-199b-3p hsa-miR-183-5p
7 hsa-miR-23a-3p hsa-let-7g-5p hsa-miR-200b-3p
8 hsa-let-7i-5p hsa-miR-30d-5p hsa-miR-29c-3p
9 hsa-miR-199b-3p hsa-miR-100-5p hsa-miR-145-5p
10 hsa-miR-146a-5p hsa-let-7i-5p hsa-miR-205-5p
11 hsa-miR-186-5p hsa-miR-125b-5p hsa-miR-200a-3p
12 hsa-miR-200a-3p hsa-miR-30a-5p hsa-miR-141-3p
13 hsa-let-7d-5p hsa-miR-145-5p hsa-miR-126-3p
14 hsa-let-7c-5p hsa-miR-29a-3p hsa-miR-99a-5p
15 hsa-miR-135b-5p hsa-miR-182-5p hsa-miR-16-5p
16 hsa-let-7e-5p hsa-miR-200a-3p hsa-miR-26a-5p
17 hsa-miR-17-5p hsa-miR-23a-3p hsa-miR-23a-3p
18 hsa-miR-19b-3p hsa-let-7c-5p hsa-miR-26b-5p
19 hsa-miR-1-3p hsa-miR-146a-5p hsa-miR-10b-5p
20 hsa-miR-194-5p hsa-miR-125a-5p hsa-miR-185-5p
List is in the decreasing order of euclidean distance values between expression
levels of normal and tumour samples
and is listed top in the lung cancer samples of our study.
hsa-miR-143 has potential role in predicting survival of
bladder cancer patients [47]. Our study shows that hsa-
miR-143 is the most widely differed microRNA in bladder
cancer data set.
Fig. 2 Performance measures of cancer prediction systems: precision -
obtained by SVMs with Pearson VII kernel(PUK) (c = 1, i = 1×10−12,
ω = 1, σ = 1), when 10 fold cross validation test is performed on
input data. LT and LNT: Positive and negative samples of lung cancer,
BT and BNT: Positive and negative samples of carcinomas of the
bladder, HT and HNT : Positive and negative hepatocellular carcinoma
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Fig. 3 Performance measures of cancer prediction systems: recall -
obtained by SVMs with Pearson VII kernel(PUK) (c = 1, i = 1×10−12,
ω = 1, σ = 1), when 10 fold cross validation test is performed on
input data. LT and LNT: Positive and negative samples of lung cancer,
BT and BNT: Positive and negative samples of carcinomas of the
bladder, HT and HNT : Positive and negative hepatocellular carcinoma
The cancer prediction system were developed using
Support Vector based classifier model. When the system
is trained and tested with 10 fold cross validation, the
prediction accuracy is 97.56% for lung cancer, 97.82% for
hepatocellular carcinoma and 95.0% for carcinomas of the
bladder. Figure 2 shows the precision and Fig. 3 shows
the recall obtained from the experiment. Predicted results
did not contain any false positive in the case of positive
samples of lung cancer, negative samples of hepatocellular
carcinoma and carcinomas of the bladder.
Even though cross validation is an effective method for
validation when limited number of samples are available,
we verified the developed model using separate test set
and independent test set. Out of 41 samples of lung can-
cer, 32 were used for training the model and the remaining
9 samples were used to test it. There was only one wrong
prediction, which was a false negative prediction. Sim-
ilarly, for hepatocellular carcinoma we trained with 33
instances and tested the model using 13 instances. Again
there was only one wrong prediction and the accuracy
is 92.8%. Table 2 shows the values obtained for different
performance measures on separate test sets. Further, we
have used 9 lung cancer samples from another experi-
ment to conduct an independent test (SRP040720). When
tested with the model trained by the original 41 samples,
all other predictions were correct except two. Similarly
for hepatocellular carcinoma, we used another data set
containing just 4 samples and there were no wrong predic-
tions (SRP065616). Thus, our model is giving promising
result with separate and independent tests. The test sam-
ples used for validation are given as Additional file 7. Also,
library preparation strategy, source, layout and selection
method were the same for the test and the training data.
We extended the validation of classifier model by
increasing the number of negative samples in the data
set. microRNA profiling has been repeated for each set of
microRNAs specific to each type of cancer. For example,
lung cancer specific microRNAs are profiled using data
samples of hepatocellular carcinoma and carcinomas of
the bladder. Expression values were normalized, appended
to the negative set and the cancer prediction system was
trained again. Table 3 shows the result obtained from the
extended sample set. The resultant accuracy were 97.56%,
97.82% and 100% , respectively for lung cancer, hepatocel-
lular carcinoma and carcinomas of the bladder. Though
the number of samples were increased by three fold, preci-
sion values obtained were 97.5%, 98.3% and 99.2% and the
recall values were 97.5%, 98.3% and 99.2%. Figure 4 shows
ROC curves of the experiment conducted with higher
number of negative samples. The area under ROC curve is
a measure of the discriminatory power of the classifier. In
the case of lung cancer samples, True Positive Rate (TPR)
touched 0.90 while False Positive Rate (FPR) was just 0.01,
and when FPR was less than 0.09, the TPR crossed 0.99.
Figures 5 and 6 shows the accuracy and the precision
of prediction when number of attributes(microRNA) used
in the samples were reduced. We have obtained an accu-
racy value of 90% or higher, when a minimum of 24, 26
and 17 attributes were used in lung cancer, hepatocellular
carcinoma and carcinomas of the bladder samples, respec-
tively. Similarly, to predict with a precision value as 90% or
higher, the number of attributes used were 24, 27 and 20
for lung cancer, hepatocellular carcinoma and carcinomas
of the bladder samples, respectively.
Discussion
Early detection is important in the successful treatment
of cancer or any other chronic disease. There are many
molecular biological techniques available, but they may
often expensive and may undergo long diagnostic proce-
dures. We developed a computational method to predict
incidences of cancer by using differential expression of
specific set of microRNAs. NGS sequencing techniques
have evolved to an extent where the cost of experiment
is becoming cheaper. This makes NGS based microRNA
profiling a feasible option to find aberrant expression of
microRNAs. Our prediction system is designed in such
Table 2 Prediction performances when separate training and test data were used
Cancer type Number of training samples Number of test samples TP rate FP rate Precision Recall Accuracy
Lung cancer 32 9 0.889 0.089 0.911 0.889 0.9
Hepato cellular carcinoma 33 13 0.9375 0.063 0.917 0.938 0.923
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Table 3 Accuracy, precision and recall values obtained when
additional negative data samples were used
Cancer types TP TN FP+FN Accuracy Precision Recall
Lung cancer 21 100 3 97.58 0.951 0.967
Hepatocellular carcinoma 24 97 2 98.37 0.975 0.975
Bladder cancer 10 103 1 99.12 0.954 0.991
a way to predict any type of cancer, provided the system
has been trained with data for that particular type of can-
cer. Presently, the system is capable of predicting three
different types of cancer.
One of the challenges in accurate detection and quan-
tification of microRNAs when compared withmRNA pro-
filing is handling of shorter length of mature microRNA
sequence. This makes the annealing of primers in reverse
transcription and PCR to a difficult process. Another bar-
rier in annealing is the inability to selective enrichment
due to the absence of a common sequence and wide vari-
ation in melting temperature due to the variance in GC
content of microRNAs. An implicit assumption in mRNA
profiling studies is that there exists a correlation of pro-
tein level and differential expression of mRNAs. Normally,
a correlation coefficient of mRNA expression versus pro-
tein expression is calculated in genome wide studies [48].
When microRNA profiling data needs to be analysed,
same yardsticks such as distribution assumptions devel-
oped for a typical mRNA assay are not suitable. The
variation in total microRNA levels in different samples
and dynamic range of expression levels are challenges to
be addressed in microRNA profiling. A single microRNA
may interact with several mRNAs and a single mRNA
may get affected by several microRNAs. Several com-
putational algorithms have been developed for finding
potential target sites. A combined effort of computational
Fig. 4 ROC curves: Comparison of ROC curves of three cancer
predictors. The highest coverage is for carcinomas of the bladder
predictor
Fig. 5 Prediction accuracy versus numbers of attributes (microRNAs).
Accuracy of prediction is above 90% when atleast 24 microRNAs are
used in the experiment for lung cancer samples, 26 microRNAs for
hepatocellular carcinoma samples and 20 microRNAs for carcinomas
of the bladder samples
and experimental validation of target sites which fur-
ther extend to the identification of variation in protein
level expression might contribute to get a comprehensive
insight in tumorigenesis.
Biomarkers help to assess disease status and act as an
aid for early diagnosis for many types of cancer [49, 50].
Better results were obtained when combination of mul-
tiple biomarkers were used, rather than their individual
predictions [51]. Studies related to the use of microRNA
as a potential biomarker in cancer diagnosis and prognosis
reckonedmicroRNA profiling as a signature identification
scheme [52]. Difference in microRNA expression can be
detected from affected tissues, from circulating tumour
cells in blood samples and by the detection of exosomic
microRNAs in the microenvironment of tumour [53]. To
translate the method suggested in this paper into a good
clinical alternative for cancer detection, it is essential to
fix RNASeq experiment and its parameters for microRNA
Fig. 6 Precision versus number of attributes (microRNAs). Precision of
prediction is above 90% when atleast 24 microRNAs are used in the
experiment for lung cancer samples, 27 microRNAs for hepatocellular
carcinoma samples and 17 microRNAs for carcinomas of the bladder
samples
Salim et al. BMC Cancer  (2017) 17:77 Page 8 of 9
profiling for specific cancer types. The advantage of algo-
rithm discussed in this paper is that, expression profiling
needs to be conducted for a limited number of microR-
NAs. At the same time, selection of microRNAs associ-
ated with each specific cancer type is a very difficult task,
as some microRNAs are associated with several diseases.
Conclusions
The exact molecular mechanism behind gene expression
regulation of microRNAs is not unveiled completely. But,
increasing evidences with experimental proofs are avail-
able for the association between microRNAs and different
diseases. The progress in Next Generation Sequencing
added great momentum in microRNA research. Many
studies related to differential expression of microRNAs in
specific diseases/cancer are in literature, but development
of cancer prediction system using microRNA profiling is
a novel approach.In this paper, we present a method to
predict the incidence of cancer by analyzing the NGS data
based on disease specific microRNAs. When the exper-
iments were conducted with lung cancer, hepatocellular
carcinoma and carcinomas of the bladder samples, the
obtained accuracies of prediction were around 97% in
cross validation. Independent and separate tests too gave
promising results. Thus, profiling of microRNA in any
accepted manner is a useful method in forecasting human
cancers as well as other diseases in which the system is
trained. We hope this could be further extended for the
development of more comprehensive prediction systems.
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